Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, et al.
Cancer Discovery (2023) Vol. 13, Iss. 5, pp. 1210-1229
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Understanding the complexity of p53 in a new era of tumor suppression
Yanqing Liu, Zhenyi Su, Omid Tavana, et al.
Cancer Cell (2024) Vol. 42, Iss. 6, pp. 946-967
Open Access | Times Cited: 93
Translating p53-based therapies for cancer into the clinic
Sylvain Peuget, Xiaolei Zhou, Galina Selivanova
Nature reviews. Cancer (2024) Vol. 24, Iss. 3, pp. 192-215
Closed Access | Times Cited: 55
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wei Wang, Najah Albadari, Yi Du, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 414-453
Open Access | Times Cited: 31
Pharmacological reactivation of p53 in the era of precision anticancer medicine
Amos Tuval, Charlotte Strandgren, Angelos Heldin, et al.
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 2, pp. 106-120
Closed Access | Times Cited: 39
Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
Jinze Shen, Qurui Wang, Yunan Mao, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
Multi-stage mechanisms of tumor metastasis and therapeutic strategies
Zaoqu Liu, Jingqi Chen, Yuqing Ren, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 12
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Youyi Huang, Xiaofang Che, Peter Wang, et al.
Seminars in Cancer Biology (2024) Vol. 101, pp. 44-57
Closed Access | Times Cited: 11
Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer
Jasmin Linh On, Sakineh Ghaderi, Carina Rittmann, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1078-1078
Open Access | Times Cited: 1
p53 biology and reactivation for improved therapy in MDS and AML
Joanna Zawacka‐Pankau
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression
Alexandra Indeglia, Maureen E. Murphy
Critical Reviews in Biochemistry and Molecular Biology (2024) Vol. 59, Iss. 1-2, pp. 128-138
Open Access | Times Cited: 7
FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia
Yuxin Tan, Lilan Xin, Qian Wang, et al.
Cancer Letters (2024) Vol. 592, pp. 216933-216933
Closed Access | Times Cited: 7
An Overview of PROTACs Targeting MDM2 as a Novel Approach for Cancer Therapy
Huiwen Li, Xinhui Cai, Xiaoyu Yang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116506-116506
Closed Access | Times Cited: 6
Sanggenol L induces ferroptosis in non-small cell lung cancer cells via regulating the miR-26a-1-3p/MDM2/p53 signaling pathway
Rong Fu, Yujie You, Yuqing Wang, et al.
Biochemical Pharmacology (2024) Vol. 226, pp. 116345-116345
Closed Access | Times Cited: 6
Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens
Ali Alaseem
Saudi Pharmaceutical Journal (2023) Vol. 31, Iss. 10, pp. 101790-101790
Open Access | Times Cited: 14
Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer
Long Lin, Xiangyu Fei, Liucui Chen, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
PROTAC: Novel degradable approach for different targets to treat breast cancer
Zhenjie Wang, Siyao Che, Zhiqiang Yu
European Journal of Pharmaceutical Sciences (2024) Vol. 198, pp. 106793-106793
Open Access | Times Cited: 5
Targeting Smurf1 to block PDK1–Akt signaling in KRAS-mutated colorectal cancer
Zhiqiang Peng, Fang Wei, Bo Wu, et al.
Nature Chemical Biology (2024)
Closed Access | Times Cited: 4
ADAR1 Regulates Lipid Remodeling through MDM2 to Dictate Ferroptosis Sensitivity
Che-Pei Kung, Nick D. Terzich, Ma Xenia G. Ilagen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Purine-rich element binding protein alpha: a DNA/RNA binding protein with multiple roles in cancers
Shiyi Yu, Chengyang Jiang, Yawen Yang, et al.
Molecular Medicine (2025) Vol. 31, Iss. 1
Open Access
Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer: in vitro and in vivo anticancer activities and newly discovered effects on cancer metabolic pathways
Wei Wang, Mariela C Aguilar, Sayantap Datta, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression
Yaxuan Zhou, Rinka Nakajima, Mashiro Shirasawa, et al.
Biology (2023) Vol. 12, Iss. 12, pp. 1511-1511
Open Access | Times Cited: 12
Spindle apparatus coiled‐coil protein 1 (SPDL1) serves as a novel prognostic biomarker in triple‐negative breast cancer
Xian‐yan Yang, Xiaoxia Zheng, Xuejia Zhai, et al.
PROTEOMICS - CLINICAL APPLICATIONS (2024) Vol. 18, Iss. 4
Closed Access | Times Cited: 4
The novel piperine derivative MHJ-LN inhibits breast cancer by inducing apoptosis via p53 activation
Hongyu Ren, Qi Gao, Mengmeng Wang, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer
Yan Li, Guangyu Li, Chenwei Zuo, et al.
European Journal of Medicinal Chemistry (2024) Vol. 270, pp. 116367-116367
Closed Access | Times Cited: 3
MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation
Sylvain Peuget, Galina Selivanova
Cancer Discovery (2023) Vol. 13, Iss. 5, pp. 1043-1045
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top